FranceFrance

Cytoo secures financing

30.09.2009

Grenoble – French specialists in high content screening (HCS), Cytoo SA, have secured EUR3m in a second funding round led by its new investor Auriga Partners. The one year old company said it will use the money to expand its business internationally, hire new staff, and to strengthen R&D. The start-up recently launched a micropatterned glass substrate called CYTOOchip™, which normalises cell architecture by fixing the cell in a specific manner on the glass substrate, thus reducing cell variability. The technology platform aims to improve cell-based assays, and has a wide range of biopharmaceutical applications, including cell signalling, cell adhesion and polarity, cell division, and precise protein colocalisation.

FranceFrance

11.06.2011

Montpellier – French researchers have identified the factor that renders human dendritic and myeloid cells largely refractory to HIV-1 infection. Overexpression of the SAMHD1 protein in cell culture effectively blocked infection...

FranceFrance

10.06.2011

Paris/Berlin – Germany and France are establishing a new form of cross-border cooperation in the life sciences. The French public health research institute Inserm and the German Helmholtz Association have agreed to build up joint...

FranceFrance

10.05.2011

Pomacle/Paris/Minneapolis – French/US firm BioAmber Inc. has raised US$45 million dollars in a Series B financing led by Paris-based private equity firm NAXOS Capital Partners and with participation of BioAmber's largest...

FranceFrance

02.05.2011

Paris - Sanofi-Aventis was reminded that steady income flows in the pharma buisness are a thing of the past. The French drugmaker saw its earnings fall by nearly 30 percent in the first quarter, as low swine flu vaccine sales...

FranceFrance

21.04.2011

Sophia Antipolis – French nitric oxide-donating drug specialist NicOx S.A. has withdrawn the EU Marketing Authorization Application (MAA) for ist osteoarthritis candidate naproxcinod (Beprana) after a meeting of the European...

FranceFrance

10.04.2011

Paris – French researchers under Etienne Hirsch from the Pasteur University in Paris have discovered that glucocorticoid receptors (GR) play a pivotal role in inflammation-mediated damage of dopaminergic neurons in the course of...

FranceFrance

04.04.2011

Toulouse – Three French research clusters have earmarked EUR20 million to build a pre-industrial demonstration plant in the area of white biotechnology. The new facility, will test the feasibility of industrial production of 2nd...

FranceFrance

01.04.2011

Toulouse – Three French research clusters have earmarked EUR20m to build a pre-industrial demonstration plant in the area of white biotechnology. The new facility, named Toulouse White Biotech­nology (TWB), will test the...

FranceFrance

01.04.2011

Lyon – Fuelled by governmental support, the French biotech sector experienced a vintage year in 2010, with a second generation of companies now emerging. But according to the Life Science Panorama 2010 survey, released by the...

FranceFrance

18.03.2011

Lille – Biopharmaceutical company Genfit has signed a deal with drug giant Sanofi-Aventis to discover molecules to correct mitochondrial dysfunction associated with metabolic disease. Sanofi will have exclusive worldwide rights...

Displaying results 31 to 40 out of 268

< Previous 31-40 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-france/browse/3/article/cytoo-secures-financing.html

Stock list

All quotes

TOP

  • SERODUS (N)3.05 NOK7.02%
  • SILENCE THERAPEUTICS (UK)244.75 GBP4.15%
  • SUMMIT (UK)4.03 GBP3.87%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • ALMIRALL (E)11.07 EUR-7.13%

TOP

  • SANTHERA (CH)70.65 CHF114.1%
  • ADDEX (CH)4.54 CHF108.3%
  • CELLECTIS (F)13.54 EUR103.6%

FLOP

  • THROMBOGENICS (B)8.51 EUR-52.2%
  • MERCK KGAA (D)63.67 EUR-50.6%
  • VERONA PHARMA (UK)1.20 GBP-43.4%

TOP

  • SANTHERA (CH)70.65 CHF3111.4%
  • GW PHARMACEUTICALS (UK)443.50 GBP843.6%
  • PAION (D)2.71 EUR310.6%

FLOP

  • CYTOS (CH)0.24 CHF-93.1%
  • EVOCUTIS (UK)0.21 GBP-92.6%
  • THROMBOGENICS (B)8.51 EUR-73.6%

No liability assumed, Date: 11.07.2014

Job Advert

Executive Director of the IMI Joint Undertaking

The Innovative Medicines Initiative Joint Undertaking (IMI JU) is a public-private partnership between the European Commission and the European Federation of Pharmaceutical Industries Associations (EFPIA).
The Executive Director will lead and manage the Joint Undertaking and take overall responsibility for its operations ensuring the achievement of the Joint Undertaking's objectives. more...

Current issue

All issues

Product of the week

Products

Events

All Events